Modulators of intracellular chloride concentration for treating neurodegenerative diseases with Parkinsonian Syndromes
View Patent ↗A composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.
1. A method for treating Parkinson's disease or associated disorders in a subject in need thereof, comprising administering to a subject in need thereof a daily therapeutically effective amount of bumetanide ranging from about 0.01 mg/day to about 100 mg/day,
wherein the associated disorder is progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration or Lewy body dementia, and wherein treating does not encompass preventing.
2. The method according to claim 1 , further comprising one or more active agent(s) for treating Parkinson's disease or associated disorders and/or side effects of said active agent(s).
3. The method according claim 1 , wherein a therapeutically effective amount of the composition is to be administered prior to, concurrent to, or subsequent to other active agent(s) for treating Parkinson's disease or associated disorders and/or side effects of said active agent(s).
4. The method according to claim 1 , wherein the subject is at risk of developing a neurodegenerative disease with Parkinsonian Syndromes.
5. The method according to claim 1 , wherein the subject is diagnosed with Parkinson's disease or associated disorders.
6. The method according to claim 1 , wherein the subject presents a genetic predisposition to Parkinson's disease or associated disorders.
7. The method according to claim 1 , wherein the subject is affected and/or diagnosed with an early-onset variant of Parkinson's disease.
8. The method according to claim 7 , wherein the early-onset variant of Parkinson's disease is an autosomal recessive PARK6-linked Parkinsonism.
9. The method according to claim 6 , wherein the genetic predisposition is a mutation of the PARK6-gene.
10. The method according to claim 1 , wherein the daily therapeutically effective amount of the composition to be administered to a subject, ranges from about 1 mg/day to about 5 mg/day.
11. The method according to claim 1 , wherein the daily therapeutically effective amount of the composition to be administered to a subject, ranges from about 1 mg/day to about 10 mg/day.